Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
      Description

      This study is being done to see if patients with metastatic solid tumors (hematologic malignancies and lymphoma excluded) who have a specific genetic mutation in patients' tumor (the SF3B1, U2AF1 or SRSF2 mutation), are more likely to respond to immunotherapy agents that are now commercially available.

      Conditions
      Metastatic Solid TumorSF3B1 Gene MutationSpliceosome MutationU2AF1 Gene MutationSRSF2 Gene Mutation
      Talk to us